STOCK TITAN
  1. Home
  2. News
  3. OCX

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Oncocyte Corporation (OCX) CEO Josh Riggs will present a corporate overview at the Sequire Investor Summit 2024 in San Juan, Puerto Rico. The conference is scheduled for January 23-25, 2024.
Positive
  • None.
Negative
  • None.

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/

About Oncocyte

Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for assessing therapeutic efficacy. For more information, please visit: www.oncocyte.com

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation.

About SRAX

SRAX Inc. is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com

CONTACT

Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com


The ticker symbol for Oncocyte Corporation is OCX.

The Sequire Investor Summit 2024 is scheduled for January 23-25, 2024.

The Sequire Investor Summit 2024 will take place at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

CEO Josh Riggs of Oncocyte Corporation will be presenting a corporate overview at the Sequire Investor Summit 2024.
Stock OCX logo
Oncocyte Corporation

NASDAQ:OCX

OCX Rankings

#4943 Ranked by Market Cap
#5367 Ranked by Stock Gains
N/A Ranked by Dividends

OCX Latest News

Apr 12, 2024
Oncocyte Reports Full Year 2023 Financial Results
Apr 11, 2024
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Apr 11, 2024
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Apr 9, 2024
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
Dec 6, 2023
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

OCX Stock Data

In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, In-Vitro Diagnostic Substance Manufacturing
US
Irvine

About OCX

oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.